Circulating Tumor DNA Market Size to Surpass USD 27.67 Billion by 2034

The global circulating tumor DNA (ctDNA) market is projected to expand from USD 7.96 billion in 2025 to approximately USD 27.67 billion by 2034, growing at a CAGR of 14.85%. This surge is driven by breakthroughs in precision oncology, rising demand for non-invasive cancer diagnostics, and advancements in next-generation sequencing (NGS) technology.

What Is Driving the Massive Growth in the Circulating Tumor DNA Market?

The ctDNA market is fueled by increasing cancer prevalence globally, a growing focus on personalized medicine, and the technological revolution in liquid biopsy platforms. ctDNA analysis allows for non-invasive detection of tumor DNA fragments in blood, enabling early cancer diagnosis, treatment monitoring, and minimal residual disease (MRD) assessment. The rising need for targeted therapies and emerging applications in cancer screening are further propelling this market.

Circulating Tumor DNA Market Key Insights

• The market size was USD 7.96 billion in 2025 and is forecasted to reach USD 27.67 billion by 2034.

• North America dominated the market, accounting for a 51% share in 2024.

• Asia Pacific is the fastest-growing region, expected to show the highest CAGR from 2025 to 2034.

• Next-generation sequencing (NGS) technology led the technology segment with a 48% share in 2024.

• The cancer diagnosis and screening application held 53% of the market share in 2024.

• Blood samples dominated the sample test segment with 82% market share in 2024.

• Clinical laboratories & diagnostic centers represented the largest end-user segment at 51%.

• Key market players include Guardant Health, Roche Diagnostics, Illumina, Thermo Fisher Scientific, and Natera.

Revenue Breakdown & Market Size Forecast (USD Billion)

AI is playing a pivotal role in enhancing the analytical power of ctDNA assays. Its ability to integrate large genomic datasets improves diagnostic accuracy and speeds up the interpretation of genetic alterations. By leveraging machine learning algorithms, AI enables better identification of cancer mutations and predicts treatment responses, driving personalized oncology approaches.

Moreover, the fusion of AI with ctDNA technology facilitates real-time monitoring of disease progression and treatment efficacy. This AI-driven advancement optimizes decision-making in clinical settings, making ctDNA testing more accessible and efficient for early detection and longitudinal patient management.

Which Factors Are Fueling the ctDNA Market Growth?

The primary growth drivers include:

• Increasing global cancer incidence is pushing demand for early and precise diagnostic tools.

• Rising adoption of non-invasive liquid biopsy methods as alternatives to traditional tissue biopsies.

• Technological advancements in NGS, digital PCR (dPCR), and PCR-based assays enhancing sensitivity and specificity.

• Growing investments from pharmaceutical firms and biotechnology companies focusing on precision medicine.

• Supportive regulatory frameworks and reimbursement policies facilitating clinical adoption.

What Are the Emerging Opportunities and Trends in the ctDNA Market?

Are minimal residual disease (MRD) monitoring and early cancer diagnosis key growth segments?

MRD monitoring is expected to exhibit the fastest CAGR due to its critical role in detecting trace cancer cells post-treatment, enabling timely intervention. Early cancer diagnosis using ctDNA enhances survival rates by enabling treatment at more manageable stages.

How important is geographic expansion, particularly in Asia Pacific?

Asia Pacific represents a high-potential market driven by improving healthcare infrastructure, rising cancer rates, and governmental initiatives supporting precision oncology. Emerging players and localized innovations further fuel this expansion.

Is integration of ctDNA with companion diagnostics a rising trend?

Combining ctDNA testing with companion diagnostics allows for tailored therapies, improving treatment efficacy and reducing adverse effects. This trend is becoming central to oncology care.

Circulating Tumor DNA Market Regional and Segment Analysis

North America: Dominates the market with over half of the global share due to advanced healthcare infrastructure, high cancer prevalence, and reimbursement advantages. The U.S. market alone is expected to grow to USD 10.9 billion by 2034.

Asia Pacific: Fastest-growing region backed by government support, increasing adoption of liquid biopsies, and rising oncologic burden, especially in countries like Japan, Singapore, and China.

Europe: Growth driven by strong pharmaceutical ecosystems, precision medicine initiatives, and supportive regulatory landscape. Germany leads with significant investments and innovation frontage.

Technology: Next-generation sequencing leads the segment for its multiplex capabilities; PCR-based assays and digital PCR are gaining momentum for their sensitivity and cost-efficiency.

Applications: Cancer diagnosis & screening lead the application side, while MRD monitoring is the fastest-growing application.

Sample Types: Blood dominates due to ease of collection and rich ctDNA content; urine is emerging in urological cancer contexts.

End-Users: Clinical laboratories dominate due to testing capacity; biopharma companies grow fastest by leveraging ctDNA in drug development.

Notable Breakthroughs and Companies to Watch

Recent studies presented at major conferences (e.g., AACR 2025, WCLC 2025) demonstrated ctDNA’s ability to predict cancer recurrence and refine immunotherapy application, highlighting its clinical validation. Leading companies driving these innovations include:

• Guardant Health

• Roche Diagnostics

• Illumina

• Thermo Fisher Scientific

• Natera

• QIAGEN

• Foundation Medicine

• Bio-Rad Laboratories

• Sysmex Corporation

• GRAIL

These firms are actively investing in R&D, clinical trials, and AI-assisted platforms to boost ctDNA assay accuracy and accessibility.

What Challenges and Cost Pressures Does the Market Face?

Challenges include:

• Regulatory complexities across regions delaying approvals.

• High initial costs for advanced sequencing technologies.

• Reimbursement variability impacting wide clinical adoption.

• Need for standardization in ctDNA assay protocols.

• Limited awareness in emerging markets restricting market penetration.

Despite these hurdles, continuous clinical validation and technological innovation are expected to mitigate cost and operational challenges over time.

Is There a Case Study Highlighting ctDNA’s Impact?

The VICTORI study, presented at AACR 2025, is a landmark trial demonstrating that personalized blood-based ctDNA assays can detect colorectal cancer recurrence up to 416 days earlier than imaging. This early detection offers prognostic value, enabling timely therapeutic intervention and significantly improving patient outcomes.

Read Also: Human Fibrinogen Concentrates Market